Hormone replacement therapy after breast cancer: Yes, No or maybe?

MOLECULAR AND CELLULAR ENDOCRINOLOGY

卷:525

Article

Ugras, Stacy K.¹  Rahman, Rakhshanda Layeequr² 

[1] Columbia Univ, Dept Surg, Med Ctr, New York, NY USA

[2] Texas Tech Univ, Dept Surg, Hlth Sci Ctr, Lubbock, TX 79430 USA

关键词: Breast cancer;    Hormone replacement therapy;    Estrogen;    Tibolone;    Recurrent breast cancer;   

DOI  :  10.1016/j.mce.2021.111180

来源: Elsevier

【 摘 要 】

Over nine million breast cancer survivors worldwide suffer compromised quality of life attributable to estrogen depletion related symptoms of menopause and side effects of cancer therapy. Hormone Replacement Therapy (HRT) is very effective in managing these symptoms in general population and in breast cancer survivors. However, the concern of breast cancer recurrence as a result of HRT use keeps many oncologists from using this approach in symptom management. Evidence from randomized trials, observational studies and met-analyses on the impact of HRT use on breast cancer recurrence and survival remains controversial. Climacteric symptoms in breast cancer survivors should be delineated for type and severity for methodical management. Lifestyle modifications are effective for mild symptoms, while non-hormonal pharmaceutical approaches can be used as second-line therapy for control of hot flashes, vulvo-vaginal atrophy, arthralgia, mood swings, sleep disturbance, and depression. Evidence does not conclusively render HRT, as a contraindicated approach for these patients; informed consent and shared-decision-making is a reasonable approach for HRT use in symptomatic breast cancer survivors.

【 授权许可】

Free